Linear DNA vaccine prepared by large-scale PCR provides protective immunity against H1N1 influenza virus infection in mice

Wang, Fei; Chen, Quanjiao; Li, Shuntang; Zhang, Chenyao; Li, Shanshan; Liu, Min; M, Kun; Li, Chunhua; Ma, Lixin; Yu, Xiaohui

doi:10.1016/j.vetmic.2017.05.015

Cited by 2 publications

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…and newly designed genetically engineered vaccines, such as virus-like particles (VLPs) (4), subunit vaccines (5), DNA vaccines (6), and reverse genetics-based vaccines (3). Since the first description of the immunogenic property of plasmid DNA in 1990, it has been used extensively to develop DNA vaccines against various pathogens, such as influenza virus (7,8), NDV (9), and Zika virus (10,11) and cancer (12) and HIV (13). Although the naked DNA vaccine possesses a number of advantages, such as tolerance to preexisting antibodies, there remain a number of drawbacks to the application of DNA vaccines in the field.…”

mentioning

confidence: 99%

A Novel Cre Recombinase-Mediated In Vivo Minicircle DNA (CRIM) Vaccine Provides Partial Protection against Newcastle Disease Virus

Jiang

Gao

et al. 2019

Appl Environ Microbiol

View full text Add to dashboard Cite

Minicircle DNA (mcDNA), which contains only the necessary components for eukaryotic expression and is thus smaller than traditional plasmids, has been designed for application in genetic manipulation. In this study, we constructed a novel plasmid containing both the Cre recombinase under the phosphoglycerate kinase (PGK) promoter and recombinant lox66 and lox71 sites located outside the cytomegalovirus (CMV) expression cassette. The strictly controlled synthesis of Cre recombinase in vivo maintained the complete form of the plasmid in vitro, whereas the in vivo production of Cre transformed the parental plasmid to mcDNA after transfection. The newly designed Cre recombinase-mediated in vivo mcDNA platform, named CRIM, significantly increased the nuclear entry of mcDNA, followed by increased production of mRNA and protein, using enhanced green fluorescent protein (EGFP) as a model. Similar results were also observed in chickens when the vaccine was delivered by the regulated-delayed-lysis Salmonella strain 11218, where significantly increased production of EGFP was observed in chicken livers. Then, we used the HN gene of genotype VII Newcastle disease virus as an antigen model to construct the traditional plasmid pYL43 and the novel mcDNA plasmid pYL47. After immunization, our CRIM vaccine provided significantly increased protection against challenge compared with that of the traditional plasmid, providing us with a novel mcDNA vaccine platform. IMPORTANCE Minicircle DNA (mcDNA) has been considered an attractive alternative to DNA vaccines; however, the relatively high cost and complicated process of purifying mcDNA dramatically restricts the application of mcDNA in the veterinary field. We designed a novel in vivo mcDNA platform in which the complete plasmid could spontaneously transform into mcDNA in vivo. In combination with the regulateddelayed-lysis Salmonella strain, the newly designed mcDNA vaccine provides us with an elegant platform for veterinary vaccine development.

show abstract

mentioning

confidence: 99%

A Novel Cre Recombinase-Mediated In Vivo Minicircle DNA (CRIM) Vaccine Provides Partial Protection against Newcastle Disease Virus

Jiang

Gao

et al. 2019

Appl Environ Microbiol

View full text Add to dashboard Cite

show abstract

“…Other delivery systems based on viral backbones require the use of mammalian cells with higher costs and the potential interference of the expressed transgene with defective viral growth [ 15 ]. Moreover, one recent evolution of DNA-EP technology is the use of complete synthetic DNA, which does not require the use of bacterial growth [ 16 , 17 , 18 ]. However, these technologies are still at the preclinical stage likely due to the lack of a large-scale production process as instead available for plasmid DNA production.…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity of COVID-eVax Delivered by Electroporation Is Moderately Impacted by Temperature and Molecular Isoforms

D’Alessio¹,

Lione²,

Salvatori³

et al. 2023

Vaccines

View full text Add to dashboard Cite

DNA integrity is a key issue in gene therapy and genetic vaccine approaches based on plasmid DNA. In contrast to messenger RNA that requires a controlled cold chain for efficacy, DNA molecules are considered to be more stable. In this study, we challenged this concept by characterizing the immunological response induced by a plasmid DNA vaccine delivered using electroporation. As a model, we used COVID-eVax, a plasmid DNA-based vaccine that targets the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. Increased nicked DNA was produced by using either an accelerated stability protocol or a lyophilization protocol. Surprisingly, the immune response induced in vivo was only minimally affected by the percentage of open circular DNA. This result suggests that plasmid DNA vaccines, such as COVID-eVax that have recently completed a phase I clinical trial, retain their efficacy upon storage at higher temperatures, and this feature may facilitate their use in low-/middle-income countries.

show abstract

Linear DNA vaccine prepared by large-scale PCR provides protective immunity against H1N1 influenza virus infection in mice

Cited by 2 publications

References 45 publications

A Novel Cre Recombinase-Mediated In Vivo Minicircle DNA (CRIM) Vaccine Provides Partial Protection against Newcastle Disease Virus

A Novel Cre Recombinase-Mediated In Vivo Minicircle DNA (CRIM) Vaccine Provides Partial Protection against Newcastle Disease Virus

Immunogenicity of COVID-eVax Delivered by Electroporation Is Moderately Impacted by Temperature and Molecular Isoforms

Contact Info

Product

Resources

About